These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
67 related articles for article (PubMed ID: 21348204)
21. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer. Miyake H; Hara I; Eto H BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202 [TBL] [Abstract][Full Text] [Related]
22. American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer. Basch EM; Somerfield MR; Beer TM; Carducci MA; Higano CS; Hussain MH; Scher HI; J Clin Oncol; 2007 Nov; 25(33):5313-8. PubMed ID: 17925542 [TBL] [Abstract][Full Text] [Related]
23. Possible benefits of curcumin regimen in combination with taxane chemotherapy for hormone-refractory prostate cancer treatment. Cabrespine-Faugeras A; Bayet-Robert M; Bay JO; Chollet P; Barthomeuf C Nutr Cancer; 2010; 62(2):148-53. PubMed ID: 20099188 [TBL] [Abstract][Full Text] [Related]
24. Novel biological agents for the treatment of hormone-refractory prostate cancer (HRPC). Papatsoris AG; Karamouzis MV; Papavassiliou AG Curr Med Chem; 2005; 12(3):277-96. PubMed ID: 15723619 [TBL] [Abstract][Full Text] [Related]
25. Androgen resistance in prostate cancer. Waxman J; Ngan S Br J Cancer; 2008 Jan; 98(1):1. PubMed ID: 18182971 [No Abstract] [Full Text] [Related]
26. [Value of targeted therapy for prostate cancer]. Börgermann C; Vom Dorp F; Schenck M; Becker M; Hess J; Rübben H Urologe A; 2008 Oct; 47(10):1315-9. PubMed ID: 18587554 [TBL] [Abstract][Full Text] [Related]
28. EGFR Targeting in Hormone-Refractory Prostate Cancer: Current Appraisal and Prospects for Treatment. Guérin O; Fischel JL; Ferrero JM; Bozec A; Milano G Pharmaceuticals (Basel); 2010 Jul; 3(7):2238-2247. PubMed ID: 27713352 [TBL] [Abstract][Full Text] [Related]
29. Innovative therapies for prostate cancer treatment. Syed S; Tolcher A Rev Urol; 2003; 5 Suppl 3(Suppl 3):S78-84. PubMed ID: 16985955 [TBL] [Abstract][Full Text] [Related]
30. New target for resistant prostate cancer. Parks L Ther Deliv; 2014 Jun; 5(6):617. PubMed ID: 25226622 [No Abstract] [Full Text] [Related]
31. [The mechanisms of drug resistance in prostate cancer]. He Y; Liu YG; Cen S; Zhou JM Yao Xue Xue Bao; 2015 Jul; 50(7):797-801. PubMed ID: 26552138 [TBL] [Abstract][Full Text] [Related]
32. Apoptosis in hormone-responsive malignancies. Denmeade SR; McCloskey DE; Joseph IB; Hahm HA; Isaacs JT; Davidson NE Adv Pharmacol; 1997; 41():553-83. PubMed ID: 9204159 [No Abstract] [Full Text] [Related]
34. The interplay of microbiota and hormone regulation in men with prostate cancer. Markowski MC; Sfanos KS Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):935-936. PubMed ID: 34007013 [No Abstract] [Full Text] [Related]
37. Hormone refractory prostate cancer (HRPC): present and future approaches of therapy. Di Lorenzo G; De Placido S Int J Immunopathol Pharmacol; 2006; 19(1):11-34. PubMed ID: 16569343 [TBL] [Abstract][Full Text] [Related]
38. Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy. Berry W; Eisenberger M Oncologist; 2005; 10 Suppl 3():30-9. PubMed ID: 16368869 [TBL] [Abstract][Full Text] [Related]
39. [Targeted therapies for hormone-refractory prostate cancer]. Song HZ; Chen LB Zhonghua Nan Ke Xue; 2010 Dec; 16(12):1108-12. PubMed ID: 21348204 [TBL] [Abstract][Full Text] [Related]